ArticleClinical rheumatology2020

Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study.

Kosuke Ebina et al.PubMed ↗Publisher ↗

No numbers read from the abstract.